FOXP3 and neoplasm: Recent reports demonstrated that FOXP3+ tumor-infiltrating lymphocytes (TILs) were associated with improved overall survival (OS) in HNSCC patients (HR: 0.80; 95% CI: 0.70–0.92) [40,41].